Clinical Trials Browser

Not yet recruiting × Carcinoma, Non-Small-Cell Lung × Paclitaxel × Clear all

NCT06694454 2026-03-18

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Not yet recruiting

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT07472647 2026-03-16

SYS6090 Combination Therapy in Advanced Lung Cancer

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT07416474 2026-02-20

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07020065 2026-01-21

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07247786 2025-12-30

MIGRANT

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms

NCT07309952 2025-12-30

SACTION 2501

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07274384 2025-12-10

HYPERBOLIC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

NCT07001618 2025-07-23

IMMUNOLIFE2

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06475755 2024-06-26

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06297811 2024-03-07

Myeloprotection With Trilaciclib in Pan-cancer Population

Phase 2 Not yet recruiting

BreastGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT05990127 2023-08-14

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung